Max Healthcare Institute Ltd

- Network gross revenue grew 24% YoY to INR 5,266 crore in the recent quarter, indicating strong ongoing growth. - Existing units delivered 17% like-for-like revenue growth, reflecting healthy organic expansion. - New units contributed INR 278 crore, supporting incremental growth. - International patient revenue grew 25% YoY, largely volume-driven, contributing to diversification. - Max Lab and Max@Home segments posted 16-20% revenue growth, indicating asset-light divisions also scaling well. - Expansion projects underway with capacity additions (e.g., Lucknow to 550 beds, Saket 550 beds, Mohali 400 beds) expected to drive future volume and revenue growth. - Brownfield expansions (Nanavati, Max Smart) expected to deliver immediate positive EBITDA, supporting margin expansion. - Management expects good revenue flow from new beds with expected margin expansion from brownfield projects. - Continued investment in growth with INR 1,100 crore capex forecasted in H2 FY26 to support future scaling.

- Max Healthcare expects continued strong growth momentum in FY26, with Q2 revenue up 21% YoY and operating EBITDA up 23% YoY, marking 20 consecutive quarters of growth. - Existing units delivered 14% revenue growth and 19% EBITDA growth, indicating stable core operations. - Brownfield expansions (Nanavati & Max Smart) are expected to ramp up rapidly with immediate EBITDA contribution and higher margins. - New bed additions, especially brownfield expansions, will see operating leverage and margin expansion once fully commissioned. - International patient revenue grew 25% YoY, driven mainly by volume growth, supporting top-line expansion. - ARPOB growth for existing hospitals is around 7% YoY, with balance from new hospitals influencing the blended figure. - Profit after tax (PAT) grew 16% YoY (excluding one-time tax benefit), and as new units mature, PAT and EPS growth are expected to accelerate. - Capex is ongoing, with INR 2,000+ crore deployed in expansions, expected to contribute positively in subsequent quarters.

- The document does not explicitly mention a current or expected order book or pending orders in a conventional business or construction sense. - However, ongoing expansion projects and capacities under development can be considered as part of pending operational capacities or projects: - Max Lucknow capacity to increase from 413 to 550 beds by end of FY 2026. - 501 beds at Sector 56, Gurgaon under progress. - 100 beds at Max Nagpur awaiting clearance; expected to complete in 24 months post-approval. - 397 beds at Patparganj expected completion by FY 2028. - 550 beds at Max Vikrant (Saket) expected in 40 months after commissioning of Max Smart. - 400 beds at Zirakpur, Mohali expected completion by end of calendar year 2027. - 140 beds at Max Vaishali project in demolition and approvals phase; 24 months post-approval. - 500 beds at Thane expected delivery in 42 months. - 250 beds at Pitampura, Delhi in planning stage; 36 months construction. - Brownfield towers at Nanavati-Max (268 beds) and Max Smart (400 beds) being commissioned imminently. This represents a substantial project pipeline reflecting the company’s growth trajectory rather than a traditional order book.

- Network capex spent in H1 FY26 was around INR 900 crore; expected to be higher in H2 at approx. INR 1,100 crore. - Ongoing expansion projects and facility upgrades incurred INR 891 crore investment in H1. - Land purchase for brownfield expansion at Max Vaishali cost INR 131 crore. - Various ongoing and planned projects with bed capacity and timelines: - Max Lucknow expansion from 413 to 550 beds by FY26-end. - 501 beds at Sector 56 Gurgaon progressing. - 100 beds at Max Nagpur to complete within 24 months after environmental approvals. - 397 beds at Patparganj expected by FY28. - 550 beds at Max Vikrant (Saket) targeted within 40 months post commissioning Max Smart beds. - 400 beds at Zirakpur, Mohali expected by end of 2027. - 140 beds at Max Vaishali with demolition completed, approvals pending. - 500 beds at Thane planned, expected in 42 months. - 250 beds at Pitampura, Delhi anticipated in 36 months post building approvals.

- The transcript does not explicitly mention any current or planned fundraising through debt or equity. - The company has taken borrowings recently to fund acquisitions (e.g., Jaypee for ~INR 2,000 crore), but no new fundraising initiatives are outlined. - The net debt for the network stands at INR 2,067 crore as of the latest quarter, up from INR 1,755 crore in June 2025, primarily due to ongoing expansions and acquisitions. - There is ongoing capital expenditure on expansion projects (around INR 1,100 crore expected in second half of the year). - Management has not indicated any immediate plans for fresh debt or equity issuance in this call. - Cash flow generation and debt repayments are continuing, with free cash flow reported during the period. In summary, no explicit mention of new fundraising activities via debt or equity in the near term.